The DOI matches its Crossref record; 152 of the 153 references it cites were found in a registry or an index; 108 of the 183 sources its claims cite were checked for support.
Updated recommendations for the treatment of Neisseria gonorrhoeae, Chlamydia trachomatis, and Treponema pallidum (syphilis) and new recommendations on syphilis testing and partner services: Web Annex A. Evidence-to-decision framework and systematic review to update the WHO treatment recommendations for Neisseria gonorrhoea
Overview
CoChat Summary
TL;DR
WHO's 2024 guideline update revises treatment recommendations for gonorrhoea, chlamydia and syphilis in pregnancy, and adds new recommendations on dual treponemal/non-treponemal syphilis rapid diagnostic tests, syphilis self-testing, and STI partner services. The updates are driven by rising antimicrobial resistance and the need to expand syphilis testing coverage toward the 2030 global targets.
Key findings
- Updated gonorrhoea treatment: ceftriaxone 1 g intramuscularly as a single dose (dose increased), with cefixime 800 mg, spectinomycin 2 g plus azithromycin 2 g, or gentamicin 240 mg plus azithromycin 2 g as alternatives (conditional recommendation, low certainty). WHO estimates 82.4 million new gonorrhoea cases in 2020; 20 of 59 countries (34%) reported reduced susceptibility or resistance to ceftriaxone in 2019–2020.
- Updated chlamydia treatment: doxycycline 100 mg twice daily for 7 days is now preferred over azithromycin, which is reserved for other infections such as *Mycoplasma genitalium* (conditional, moderate certainty). In 11 RCTs, cure rates were 92.5% with azithromycin and 94.4% with doxycycline; adverse events 18% and 21.8% respectively. For pregnant/breastfeeding women, azithromycin 1 g single dose remains a strong recommendation (moderate certainty).
- Syphilis in pregnancy: benzathine penicillin G 2.4 million units remains recommended (strong recommendation, very low certainty); reported effectiveness at preventing transmission ranged from 96% to 100% across studies representing over 5000 participants. Azithromycin was deleted as an alternative.
- New service-delivery recommendations: dual treponemal/non-treponemal RDTs (strong recommendation, low certainty; pooled treponemal sensitivity 93% [95% CI 86–97%], specificity 98% [96–99%]; non-treponemal sensitivity 90% [82–95%], specificity 97% [92–99%]); syphilis self-testing (conditional, low certainty; meta-analysis of two RCTs showed more than a four-fold increase in testing uptake); and STI partner services offered as a range of voluntary options (strong recommendation, low certainty).
Methods
- Developed per the 2014 WHO handbook for guideline development, using GRADE to assess evidence and formulate recommendations; evidence-to-decision frameworks and summary-of-findings tables were prepared for each question.
- Multiple systematic reviews were conducted or updated (searches to August 2023 for treatment; 2010–July 2022 for dual RDTs; 2000–October 2022 for self-testing; to February 2020 for partner services), plus a modelling study for dual RDTs. A 34-member Guideline Development Group (all six WHO regions) made recommendations by consensus at a virtual meeting in November 2022, with a follow-up meeting on 30 May 2023; a 15-member External Review Group peer-reviewed the guidelines.
- PICO questions covered increased-dose gonorrhoea therapy, multi-dose doxycycline versus single-dose azithromycin, alternative antibiotics versus benzathine penicillin in pregnancy, dual T/NT RDTs, syphilis self-testing, and partner services.
Limitations
- Stated: certainty of evidence is low or very low for most updated treatment recommendations; gonorrhoea evidence comes largely from non-comparative studies conducted before resistance changes; no RCTs were identified for dual treponemal/non-treponemal RDTs; syphilis self-testing evidence came from only about seven studies (two RCTs), all among key populations in Asia, Africa and the Americas, using only blood-based treponemal or dual HIV/syphilis tests (no non-treponemal self-tests); no studies addressed provider–patient referral or social network approaches for STIs; social harm monitoring systems are limited.
- Evident from the text: currently no WHO-prequalified dual treponemal/non-treponemal RDTs or syphilis self-test products are available for procurement, which constrains immediate implementation of two of the new recommendations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
50 Valid · 12 Not valid · 49 Not checked · 143 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Similar to health workers, patients' main reason for preferring simple patient referral was to maintain privacy (124, 128, 129).”
What the sources say
- Disputedcites [124] Quinn C, Nakyanjo N, Ddaaki W, Burke VM, Hutchinson N, Kagaayi J et al. HIV Partner notification values and preferences among sex workers, fishermen, and mainland community members in Rakai, Uganda: a qualitative study. AIDS Behav. 2018;22(10):3407-16 (https://doi.org/10.1007/s10461-018-2035-3). sourceExperimental — accuracy not yet measured
The Results section on passive referral (page unavailable) says participants valued it for demonstrating faith and building trust in intimate relationships, not for maintaining privacy. The Results section on provider referral instead associates anonymity with preference for provider referral, particularly among sex workers and fishermen. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [128] Klisch SA, Mamary E, Diaz Olavarrieta C, Garcia SG. Patient-led partner notification for syphilis: strategies used by women accessing antenatal care in urban Bolivia. Soc Sci Med. 2007;65(6):1124-35 (https://doi.org/10.1016/j. socscimed.2007.04.025). doi:10.1016/j
- Partly supportedcites [129] Njozing BN, Edin KE, Sebastian MS, Hurtig AK. "If the patients decide not to tell what can we do?" – TB/ HIV counsellors' dilemma on partner notification for HIV. BMC Int Health Hum Rights. 2011;11:6 (https://doi. org/10.1186/1472-698X-11-6). sourceExperimental — accuracy not yet measured
In Results > Dealing with partner notification (page unavailable), a counsellor reports that some patients would rather notify partners themselves than have a counsellor do it. The paper also discusses patients’ confidentiality concerns, but it does not establish that maintaining privacy was patients’ main reason for preferring patient referral. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“resistance to ciprofloxacin was reported by all 58 reporting countries (100%”
What the sources say
- Partly supportedcites [9] Unemo M, Lahra MM, Escher M, Eremin S, Cole MJ, Galarza P et al. WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017–18: a retrospective observational study. Lancet Microbe. 2021;2(11):e627-e36 (https:// doi.org/10.1016/S2666-5247(21)00171-3). sourceExperimental — accuracy not yet measured
The passage labeled “Role of the funding source” (page not provided) reports ciprofloxacin resistance in all reporting countries (100%), but it gives 70 countries in 2017–18, not 58 in 2019–20. The cited paper therefore supports the all-countries finding, not the claimed count or period. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Since 2015, the international spread of ceftriaxone-resistant gonococcal strains has been confirmed (10)”
What the sources say
- Supportedcites [10] Lahra MM, Martin I, Demczuk W, Jennison AV, Lee KI, Nakayama SI et al. Cooperative recognition of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain. Emerg Infect Dis. 2018;24(4):735-40 (https://doi. org/10.3201/eid2404.171873). source
The Abstract identifies the first FC428 ceftriaxone-resistant isolate in Japan in January 2015 and reports closely related isolates in other countries. The Discussion says the findings provide evidence of sustained international transmission and that the strain appears to have circulated globally for more than two years. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Isolates with resistance to azithromycin were reported by 42 of 47 countries (89%”
What the sources say
- Partly supportedcites [9] Unemo M, Lahra MM, Escher M, Eremin S, Cole MJ, Galarza P et al. WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017–18: a retrospective observational study. Lancet Microbe. 2021;2(11):e627-e36 (https:// doi.org/10.1016/S2666-5247(21)00171-3). sourceExperimental — accuracy not yet measured
Our copy of Unemo et al. reports exactly this kind of statement but for 2017–18: 'Isolates with resistance to azithromycin were reported by 51 of 61 reporting countries (84%; up from 81% in 2015-16)' (Results, p. ~3), and the Study design section fixes the data window as isolates collected January 2017–December 2018 from 73 countries (61 reporting azithromycin data). The time frame and all three numbers attributed here (2019–2020, 42 of 47 countries, 89%) do not appear anywhere in our copy; searches for '2019-2020', '42 of 47' and country-count tables returned only 2017–18 figures (e.g. 44 [76%] of 58 countries in 2018; 40 [69%] reporting ≥5% resistance). The only 89% azithromycin figure in our copy is regional — 24 (89%) of 27 Euro-GASP countries in the WHO European region in 2018 — not 42 of 47 global reporting countries. So the direction of the finding (most reporting countries detected azithromycin-resistant isolates) is supported, but the specific surveillance round and counts are not from this paper. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“11 of 41 countries (27%) reported reduced susceptibility or resistance to cefixime”
What the sources say
- Could not verifycites [9] Unemo M, Lahra MM, Escher M, Eremin S, Cole MJ, Galarza P et al. WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017–18: a retrospective observational study. Lancet Microbe. 2021;2(11):e627-e36 (https:// doi.org/10.1016/S2666-5247(21)00171-3). sourceExperimental — accuracy not yet measured
Our copy of Unemo et al. 2021 covers only WHO GASP/GLASS data for 2017–18; no passage addresses 2019–20 surveillance, and the figures '11 of 41 countries (27%)' for cefixime do not appear anywhere in it. The closest cefixime statements are for this earlier period: in 2018, 19 (39%) of 49 countries reporting decreased susceptibility or resistance to cefixime, and for 2017–18 combined, 24 of 51 reporting countries (47%) (Results, 'Role of the funding source' section). The only 27% cefixime figure in the table is a different metric — 8 (27%) of 30 countries in the WHO European region with ≥5% decreased susceptibility/resistance in 2017–18 — so the cited 2019–20 numbers are outside this paper's scope rather than contradicted by it. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
94 more claims · 30 with their cited sources checked
Create a free account to see all 254 claims and to verify the 9 references still open.
- It may state two separate claims as one. 100
- Probably not a substantial claim. 95
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ 2. Methods 9
“no conflicts of interest sufficient to preclude any GDG member from participating fully in the development of the guidelines were found.”
§ 2. Methods 13 > 2.6 Managing conflicts of interest
“One member was excluded from discussions related to treatment of N. gonorrhoeae because they were involved in a study on that subject.”
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Research works printed but not linked: 7
- 5 All links for references available online were accessed on 20 June 2024, unless another date is specified. https://iris.who.int/handle/10665/341412 https://iris.who.int/handle/10665/341412 https://doi.org/10.1155/2016/9315757 https://doi.org/10.1136/sextrans-2018-053778 https://doi.org/10.1371/journal.pmed.1002344 https://doi.org/10.1371/journal.pmed.1002344 https://doi.org/10.1038/s41572-019-0128-6 https://doi.org/10.1071/SH19023 https://doi.org/10.1371/journal.pone.0211720 https://iris.who.int/handle/10665/360348 https://doi.org/10.1016/S2666-5247(21)00171-3 https://doi.org/10.1016/S2666-5247(21)00171-3 https://doi.org/10.3201/eid2404.171873 https://doi.org/10.3201/eid2404.171873 https://doi.org/10.2807/1560-7917.ES.2019.24.8.1900118 https://doi.org/10.1097/im9.0000000000000113 https://doi.org/10.1097/im9.0000000000000113 https://doi.org/10.1016/s1473-3099(23)00479-6 · DOI · Paper page
- [29]WHO handbook for guideline development, second edition. Geneva: World Health Organization; 2014 (https://iris. who.int/handle/10665/145714).
- [49]Abdulai M, Ayisi Addo S, Danso K, Senya K, Owusu K, Adu-Gyamfi R et al. Increasing syphilis testing coverage in antenatal care by 70% in Ghana: lessons from the rollout of dual HIV/syphilis rapid diagnostic tests [poster]. Montreal: 24th International AIDS Conference; 2022 (programme.aids2022.org/Abstract/Abstract/?abstractid=11780). https://doi.org/10.1093/cid/ciy477 https://doi.org/10.1002/14651858.CD007768.pub3 https://doi.org/10.1002/14651858.CD007768.pub3 https://doi.org/10.1093/jacamr/dlac116 https://supply.unicef.org https://iris.who.int/handle/10665/90000 https://iris.who.int/handle/10665/90000 https://www.unfpa.org/publications/implementing-comprehensive-hiv-and-sti-programmes-men-who-have-sex-men https://www.unfpa.org/publications/implementing-comprehensive-hiv-and-sti-programmes-men-who-have-sex-men https://www.undp.org/publications/implementing-comprehensive-hiv-and-sti-programmes-transgender-people https://www.undp.org/publications/implementing-comprehensive-hiv-and-hcv-programmes-people-who-inject-drugs https://www.undp.org/publications/implementing-comprehensive-hiv-and-hcv-programmes-people-who-inject-drugs https://doi.org/10.1136/sextrans-2020-054706 https://doi.org/10.1093/cid/cir671 https://doi.org/10.1093/cid/cir671 https://doi.org/10.1371/journal.pone.0175477 https://iris.who.int/handle/10665/374252 https://lawsandpolicies.unaids.org/ https://lawsandpolicies.unaids.org/ https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/stis/strategic-information https://programme.aids2022.org/Abstract/Abstract/?abstractid=11780 · DOI · Paper page
- [74]Reipold E, Van Nguyen T, Shiha G, Stvilia K, Monroe-Wise A, Wang C. Self-testing for HCV: multicountry evidence on usability and acceptability. Abstract. Boston: Conference on Retroviruses and Opportunistic Infections; 2021 (https:// www.natap.org/2021/CROI/croi_129.htm).
- [83]Rothschild C, Sedgh G, Cover J, Gerdts C, Hatzold K, Holt K et al. Sexual and Reproductive Health Self- Care Measurement Tool. Washington, DC: Self-Care Trailblazer Group; 2023 (https://doi.org/10.6084/ m9.figshare.21954377). https://doi.org/10.1136/sextrans-2020-054911 https://doi.org/10.1093/cid/ciz603 https://doi.org/10.3389/fpubh.2022.744240 https://doi.org/10.1093/cid/ciaa825 https://doi.org/10.2196/24303 https://doi.org/10.1111/hiv.12437 https://doi.org/10.1016/S2352-3018(18)30044-4 https://www.natap.org/2021/CROI/croi_129.htm https://www.natap.org/2021/CROI/croi_129.htm https://doi.org/10.1007/s10461-020-02829-x https://doi.org/10.1093/cid/ciab029 https://doi.org/10.1016/j.eclinm.2021.100991 https://doi.org/10.1186/s12916-020-01835-z https://doi.org/10.1002/jia2.25612 https://doi.org/10.1002/jia2.26020 https://doi.org/10.1371/journal.pone.0056463 https://doi.org/10.1371/journal.pone.0056463 https://doi.org/10.1097/QAD.0000000000003328 https://doi.org/10.6084/m9.figshare.21954377 https://doi.org/10.6084/m9.figshare.21954377 · DOI · Paper page
- [100]Falk L, Hegic S, Wilson D, Wirehn AB. Home-sampling as a tool in the context of Chlamydia trachomatis partner notification: a randomized controlled trial. Acta Derm Venereol. 2014;94(1):72-4 (https://doi.org/10.2340/00015555- 1624). · doi:10.2340/00015555-
- [185]Sharma M, Smith JA, Farquhar C, Ying R, Cherutich P, Golden M et al. Assisted partner notification services are cost-effective for decreasing HIV burden in western Kenya. AIDS. 2018;32(2):233-41 (https://doi.org/10.1097/ QAD.0000000000001697).
Cited by
Roditscheff, A., Egli, K., Vianin, A., Loertscher, F., Reidla, J., Wehrli, F., Risch, M., Risch, L., Hobbie, S. N., Wohlwend, N., et al. (2025) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-025-05053-4 · Cited by 4
Metadata
- Authors
- World Health Organization
- Venue
- World Health Organization eBooks
- Publisher
- World Health Organization
- Published
- 2024-07-17
- OpenAlex
- W4400769200
- Cited by
- 1
- References
- 0
- Citations by year
- 2025: 1
- FWCI
- 0.48
- Type
- book
- Language
- en
- Open access
- closed
- Locations
- World Health Organization eBooks (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Health Sciences › Medicine › Infectious Diseases › Syphilis Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Keywords
- Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum, syphilis, gonorrhea treatment, chlamydia treatment, syphilis treatment, syphilis testing, partner services, WHO treatment recommendations, sexually transmitted infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Updated recommendations for the treatment of Neisseria gonorrhoeae, Chlamydia trachomatis, and Treponema pallidum (syphilis) and new recommendations on syphilis testing and partner services: Web Annex A. Evidence-to-decision framework and systematic review to update the WHO treatment recommendations for Neisseria gonorrhoea. https://app.cochat.ai/papers/10.2471/b09099
- The paper
- World Health Organization. (2024). Updated recommendations for the treatment of Neisseria gonorrhoeae, Chlamydia trachomatis, and Treponema pallidum (syphilis) and new recommendations on syphilis testing and partner services: Web Annex A. Evidence-to-decision framework and systematic review to update the WHO treatment recommendations for Neisseria gonorrhoea. World Health Organization eBooks. https://doi.org/10.2471/b09099
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.